This trial aims to evaluate the use of the patient's own mesenchymal stem cells in the treatment of neuropathy in patients with type 1 diabetes. The trial is being conducted by the Endocrinology and Metabolism Research Institute in Teheran and proposes to recruit 20 patients by end 2013. The participants will receive an intravenous (IV) infusion of mesenchymal stem cells that have been obtained from their own bone marrow and expanded in the laboratory. Participants will be monitored for complications and changes in their condition, including sensory neurological evaluation and blood glucose control.